Searching journal content for somatostatin analogs (as phrase) in full text.

Displaying results 1-10 of 111
For checked items
  1. Review:
    • Vincenzo Marotta,
    • Maria Chiara Zatelli,
    • Concetta Sciammarella,
    • Maria Rosaria Ambrosio,
    • Marta Bondanelli,
    • Annamaria A L Colao,
    • and Antongiulio Faggiano
    Chromogranin A as circulating marker for diagnosis and management of neuroendocrine neoplasms: more flaws than fame Endocr Relat Cancer ERC-17-0269, doi:10.1530/ERC-17-0269 first published on 24 October 2017
    ...somatostatin analogs ~~~
  2. Thematic Review:
    • Rachel S van Leeuwaarde,
    • Joanne M de Laat,
    • Carolina R C Pieterman,
    • Koen Dreijerink,
    • Menno R Vriens,
    • and Gerlof D Valk
    The future: medical advances in MEN1 therapeutic approaches and management strategies Endocr Relat Cancer 24 (10) T179-T193, doi:10.1530/ERC-17-0225 first published on 2 August 2017
    ...somatostatin analogs and the newer growth hormone receptor antagonist Pegvisomant (Trainer et al. 2000). MEN1-associated PIT were considered more aggressive than sporadic PIT, and more often unresponsive to medical treatment (especially in prolactinomas) necessitating earlier surgery (O’Brien et  al ~~~
  3. Thematic Review:
    • Francesca Marini,
    • Francesca Giusti,
    • Francesco Tonelli,
    • and Maria Luisa Brandi
    Management impact: effects on quality of life and prognosis in MEN1 Endocr Relat Cancer 24 (10) T227-T242, doi:10.1530/ERC-17-0203 first published on 21 July 2017
    ...somatostatin analogs (SSAs; octreotide or lanreotide) for the control of GH over-secretion is reserved for second line therapy or for patients not eligible for surgery. Gastro-entero-pancreatic neuroendocrine tumors (GEP-NETs) GEP-NETs clinically affect 30–80% of MEN1 patients, and 80–100% in postmo ~~~
  4. Thematic Review:
    • Jerena Manoharan,
    • Max B Albers,
    • and Detlef K Bartsch
    The future: diagnostic and imaging advances in MEN1 therapeutic approaches and management strategies Endocr Relat Cancer 24 (10) T209-T225, doi:10.1530/ERC-17-0231 first published on 8 August 2017
    ...somatostatin analogs are used. Several studies on EUS have shown that it is the most sensitive imaging modality for the detection of dpNEN, especially of those smaller than 1 cm in size (van Asselt et  al. 2015, Kann et  al. 2006b). Kann and coworkers demonstrated that EUS is capable to identify MEN ~~~
  5. Thematic Review:
    • S M Sadowski,
    • G Cadiot,
    • E Dansin,
    • P Goudet,
    • and F Triponez
    The future: surgical advances in MEN1 therapeutic approaches and management strategies Endocr Relat Cancer 24 (10) T243-T260, doi:10.1530/ERC-17-0285 first published on 15 August 2017
    ...somatostatin analogs to everolimus and chemotherapy, local therapies (RFA, chemo-embolization, or radiotherapy) or peptide radio-receptor therapy (PRRT). In conclusion, there is currently no consensus available about the extent of resection in functional pNETs for patients with MEN1 and future studi ~~~
  6. Review:
    • Carole Guerin,
    • Pauline Romanet,
    • David Taieb,
    • Thierry Brue,
    • André Lacroix,
    • Frederic Sebag,
    • Anne Barlier,
    • and Frederic Castinetti
    Looking beyond the thyroid: advances in understanding of pheochromocytoma and hyperparathyroidism phenotypes in MEN2 and of non-MEN2 familial forms Endocr Relat Cancer ERC-17-0266, doi:10.1530/ERC-17-0266 first published on 5 September 2017
    ...somatostatin analogs ~~~
  7. Research:
    • Patrick Petrossians,
    • Adrian F Daly,
    • Emil Natchev,
    • Luigi Maione,
    • Karin Blijdorp,
    • Mona Sahnoun-Fathallah,
    • Renata Auriemma,
    • Alpha M Diallo,
    • Anna-Lena Hulting,
    • Diego Ferone,
    • Vaclav Hana, Jr,
    • Silvia Filipponi,
    • Caroline Sievers,
    • Claudia Nogueira,
    • Carmen Fajardo-Montañana,
    • Davide Carvalho,
    • Vaclav Hana,
    • Günter K Stalla,
    • Marie-Lise Jaffrain-Réa,
    • Brigitte Delemer,
    • Annamaria Colao,
    • Thierry Brue,
    • Sebastian J C M M Neggers,
    • Sabina Zacharieva,
    • Philippe Chanson,
    • and Albert Beckers
    Acromegaly at diagnosis in 3173 patients from the Liège Acromegaly Survey (LAS) Database Endocr Relat Cancer 24 (10) 505-518, doi:10.1530/ERC-17-0253 first published on 21 July 2017
    ...somatostatin analogs (SSA) and somatostatin receptor ligands (SRL) to the growth hormone (GH) receptor antagonist pegvisomant and dopamine agonists (Melmed 2016). Radiotherapy techniques have undergone significant developments leading to the gamma-knife used today. Modern acromegaly therapy is guide ~~~
    OPEN ACCESS ARTICLE
  8. Research:
    • Massimo Terzolo,
    • Giuseppe Reimondo,
    • Paola Berchialla,
    • Emanuele Ferrante,
    • Elena Malchiodi,
    • Laura De Marinis,
    • Rosario Pivonello,
    • Silvia Grottoli,
    • Marco Losa,
    • Salvatore Cannavo,
    • Diego Ferone,
    • Marcella Montini,
    • Marta Bondanelli,
    • Ernesto De Menis,
    • Chiara Martini,
    • Efisio Puxeddu,
    • Antonino Velardo,
    • Alessandro Peri,
    • Marco Faustini-Fustini,
    • Patrizia Tita,
    • Francesca Pigliaru,
    • Giulia Peraga,
    • Giorgio Borretta,
    • Carla Scaroni,
    • Nicoletta Bazzoni,
    • Antonio Bianchi,
    • Alessandro Berton,
    • Andreea Liliana Serban,
    • Roberto Baldelli,
    • Letizia Maria Fatti,
    • Annamaria Colao,
    • Maura Arosio,
    • and for the Italian Study Group of Acromegaly
    Acromegaly is associated with increased cancer risk: a survey in Italy Endocr Relat Cancer 24 (9) 495-504, doi:10.1530/ERC-16-0553 first published on 14 July 2017
    ...somatostatin analogs era. It was evaluated the incidence of cancer in an Italian nationwide multicenter cohort study of 1512 acromegalic patients, 624 men and 249 495–504 Correspondence should be addressed to G Reimondo Email [email protected] Key Words f acromegaly f cancer f GH f IGF1 496 ~~~
  9. Review:
    • Wouter T Zandee,
    • Kimberly Kamp,
    • Roxanne C van Adrichem,
    • Richard A Feelders,
    • and Wouter W de Herder
    Effect of hormone secretory syndromes on neuroendocrine tumor prognosis Endocr Relat Cancer 24 (7) R261-R274, doi:10.1530/ERC-16-0538 first published on 8 May 2017
    ...somatostatin analogs and everolimus can also decrease symptoms of hypersecretion and increase progression-free survival. Several factors affect the survival in patients with a functioning NET. Complications of hypersecretion negatively impact survival; however, secretion of hormones is also often a ~~~
  10. Review:
    • Maria Chiara Zatelli,
    • Erika Maria Grossrubatscher,
    • Elia Guadagno,
    • Concetta Sciammarella,
    • Antongiulio Faggiano,
    • and Annamaria Colao
    Circulating tumor cells and miRNAs as prognostic markers in neuroendocrine neoplasms Endocr Relat Cancer 24 (6) R223-R237, doi:10.1530/ERC-17-0091 first published on 7 April 2017
    ...somatostatin analogs ~~~
For checked items

Search Results

Next 10 » New Search

Modify Results

Citation format:
Results / page:
Results order:

This search

  • Alert me when new articles matching this search are published
  • Download all citations on this page to my citation manager

New Articles: issue in progress

  1. December 2017, 24 (12)
  1. Current Issue
  1. Alert me to new issues of Endocrine-Related Cancer

Most